The Company is expected to initiate the phase 1/2 BeCoMe-9 study to evaluate BE-101 in adults with severe or moderately severe ...

Percentage of telehealth visits was higher for mental health than other clinicians. HealthDay News — In 2021, 9.6% of medical ...

After a median follow-up of approximately 35.2 months, the median OS was 23.7 months for nivolumab plus ipilimumab vs 20.6 months ...

The availability of these generics is still unclear as the patent for Entresto does not expire until July 15, 2025. The Food and ...

Credit: BrainsWay. The outpatient procedure provides noninvasive magnetic stimulation through a cushioned helmet to targeted ...

Authors found that BMI of 27 or greater shows excellent diagnostic performance. HealthDay News — The optimal body mass index ...

The program automatically reduces the cost of the inhaler at the pharmacy for eligible patients with commercial insurance.

Greater use of weight management treatments seen with WNP, including bariatric surgery, low-calorie meal replacement. HealthDay ...

Results showed 30.4% of patients treated with mitapivat achieved a transfusion reduction response vs 12.6% of patients who ...

Findings showed patients treated with plozasiran 25mg and 50mg had median triglyceride reductions of -80% and -78%, respectively ...

Credit: Moderna. The approval was based on data from the phase 3 ConquerRSV trial, which included approximately 37,000 adults 60 ...

Results from LIBRETTO-121 showed a confirmed overall response rate of 48% (95% CI, 28-69). The Food and Drug Administration (FDA ...